Subscribe & listen on Soundcloud, iTunes and Google Play.
In this episode of Disruptive, Wyss Founding Core Faculty Member Dave Mooney discusses programmable nanomaterials approaches to fighting disease. Mooney explains how a cancer vaccine, developed by his team and currently in a clinical trial at the Dana-Farber Cancer Institute, can train one’s own immune system to target specific cancer cells. He also describes the development of novel hydrogels that find application in drug delivery systems and tissue regeneration. Chris Gemmiti, a member of the Wyss Institute’s Business Development team, joins the conversation to discuss the Wyss process of translation and what is involved in bringing the hydrogel drug delivery technology from bench-to-bedside.